Decera Clinical Education Oncology Podcast

Decera Clinical Education
  • 4.9 (10)
  • COURSES
  • UPDATED DAILY

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

  1. Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC

    MAR 26

    Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC

    In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including: Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important ADCs for HER2-negative/ultralow/low MBC Patient communication: best practices in discussing treatment goals and potential AEs Presenters:  Aditya Bardia, MD, MPH, FASCO Professor of Medicine Geffen School of Medicine University of California Los Angeles, California Ruta Rao, MD​ Medical Director, Rush University Cancer Center Professor of Medicine Rush University Medical Center Chicago, Illinois ​ Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc. Link to full program: https://bit.ly/47JLtBt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    19 min
  2. Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer

    MAR 25

    Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer

    Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all patients. Presenters: Ann Marie Siney, RN, MSN, ANP-BC Division of Hematology/Oncology UCLA Health Santa Monica, California Kathleen Boyle, DScPAS, PA-C  Gastrointestinal Cancer Center Dana-Farber Cancer Institute Boston, Massachusetts Link to full program: https://bit.ly/4spkxiC Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    33 min
  3. Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer

    MAR 25

    Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer

    Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of biomarker testing results to practice. Presenters: Sara Traverso, MMS, PA-C  Physician Assistant Northwestern Medicine Robert H. Lurie Comprehensive Cancer Center Genitourinary Oncology Chicago, Illinois Brenda Martone, MSN, ANP-BC, AOCNP Nurse Practitioner Northwestern Medicine Chicago, Illinois Link to full program: https://bit.ly/3PB4ZJR Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    22 min
  4. Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026

    MAR 23

    Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026

    In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including: New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer Intravesical therapies such as nadofaragene and N-803 The role of ctDNA in measurable residual disease detection Presenters: Sam S. Chang, MD, MBA Patricia and Rodes Hart Chair of Urologic Surgery Chief Surgical Officer Vanderbilt Ingram Cancer Center Nashville, Tennessee Matthew D. Galsky, MD Lillian and Howard Stratton Professor of Medicine Icahn School of Medicine at Mount Sinai Director, Genitourinary Medical Oncology Co-Leader, Cancer Clinical Investigation Program Associate Director for Translational Research Tisch Cancer Institute New York, New York Link to full program: https://bit.ly/479RgQn Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    19 min
  5. Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization

    MAR 20

    Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization

    In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making. Presenters:  Rodney Hunter, PharmD, BCOP Director of Clinical Services Memorial Hermann Texas Medical Center Clinical Pharmacy Specialist University of Texas Health Memorial Hermann Cancer Center Professor Texas Southern University College of Pharmacy and Health Sciences Clinical Adjunct Professor McGovern Medical School Houston, Texas Julia L. Ziegengeist, PharmD, BCOP Clinical Pharmacist Specialist, Breast Medical Oncology Levine Cancer, Atrium Health Charlotte, North Carolina Link to full program:https://bit.ly/46SPGlU Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    25 min
  6. From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL

    MAR 11

    From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL

    In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including: How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe Practical sequencing decisions after disease progression Emerging BTK degradersas a promising option for heavily pretreated patients Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Matthew S. Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Leader, Lymphoma Program Dana-Farber/Harvard Cancer Center Director of Clinical Research, Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Nelson Hamerschlak, MD, PhD Head of the Department of Hematology, BMT and Clinical Cell Therapy Einstein Hospital Israelita Sao Paulo, Brazil Stephen Stilgenbauer, MD Medical Director, Comprehensive Cancer Center Ulm (CCCU) Head, Early Clinical Trials Unit (ECTU) Head, Division of CLL Department of Internal Medicine III Comprehensive Cancer Center Ulm (CCCU) University of Medical Center Ulm Ulm, Germany Link to the full program: https://bit.ly/4rsZlqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    30 min
  7. 2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast

    MAR 9

    2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast

    Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc,  about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium. Presenters: Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Virginia Kaklamani, MD, DSc Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment A.B. Alexander Distinguished Chair in Oncology Leader, Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center San Antonio, Texas Link to full program:https://bit.ly/46Qv9OK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    37 min
  8. Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions

    MAR 9

    Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions

    In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including: Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy Presenters: Luis Paz-Ares, MD, PhD Head of Medical Oncology Department Hospital Universitario 12 de Octubre Associate Professor, Universidad Complutense de Madrid Madrid, Spain Christine Bestvina, MD Associate Professor University of Chicago Medicine Division of Medicine Section of Hematology/Oncology University of Chicago Medicine Chicago, IllinoisLink to full program:https://bit.ly/4rhoUuN Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    17 min
See All (236)

Ratings & Reviews

4.9
out of 5
10 Ratings

About

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Information

You Might Also Like